Earnings Releases·Nov 10, 2026, 8:21 AM ET

MaxCyte — Third Quarter 2026 Earnings Summary

Total revenue reached $10.2 million in Q3 2026, a 49% year-over-year increase driven by a 27% rise in core revenue and a $1.6 million surge in Strategic Platform License (SPL) revenue; net loss narrowed significantly to $4.8 million from $12.4 million in the prior year period.
Full Year 2026 total revenue guidance was raised to at least $34.5 million (excluding Akron acquisition impact), with management projecting approximately 15% core revenue growth in the second half of the year.
The company announced a strategic acquisition of Akron Bio to expand cell therapy manufacturing capabilities and nearly double revenue, alongside a new multi-platform license partnership with Genentech.
Cash and investments stood at $132.7 million as of September 30, 2026, though the Akron acquisition involves $105 million in expenses and $22 million drawn on a credit facility, with pro forma cash expected to range between $40.0 and $45.0 million by year-end assuming deal closure.
SPL program momentum remains strong with 28 total agreements and potential approvals from two pivotal trials as early as next year, while operating expenses decreased to $14.5 million due to reduced stock-based compensation and the absence of restructuring charges.